Immunotherapeutic Strategies for Precision Tumor Targeting
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 87
Special Issue Editors
Interests: cancer immunology; cell therapy
Interests: cancer immunology; cell therapy; drug resistance; personalised medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer immunotherapy requires the development of effective therapeutic strategies capable of eliciting an effective immune response to eradicate or control cancer. Traditional immunotherapeutic methods, such as immune checkpoint inhibitors and cancer vaccines, offer hope for enhancing the clinical response. However, even in combination with other standard therapies, including chemotherapy, there are significant challenges to its effectiveness, including immune cell exhaustion and cancer resistance, which eventually lead to relapse and death.
A better understanding of the biology of the immune tumour microenvironment (TME), the enrichment and expansion of specific immune cells, such as tumour reactive T-cells, and the gene modification of immune cells are recent novel approaches to improving cancer immunotherapy. This Special Issue focuses on promising cancer immunotherapy strategies targeting the TME and beyond, including mRNA vaccines, adoptive cell therapies, such as TILs, CAR-T cell therapy, TCR therapy, immune checkpoint inhibitors, bispecific antibodies, immunomodulation strategies, and any new innovative methods that can stimulate specific tumor immune responses.
We look forward to receiving your contributions.
Dr. Yien Ning Sophia Wong
Dr. Alvin Lee
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer vaccine
- mRNA vaccines
- CAR-T cell therapy
- TCR therapy
- immune checkpoint inhibitors
- bispecific antibodies
